CoLab is a pan-Canadian evidence-generation network comprised of leading experts in applied research, drug evaluation methodology, and data analysis.
Ensuring access to safe, effective, and clinically relevant drugs is important for Canada’s health systems. CoLab answers questions about postmarket drug safety and effectiveness for senior policy decision-makers with timely targeted evidence.
CoLab receives funding from Canada’s Drug Agency (CDA-AMC) through the
Post-Market Drug Evaluation (PMDE) Program. Postmarket drug evaluation focuses on drugs that have proceeded through the approval process and are available to patients and consumers. It helps determine if drugs used in the real-world are safe, work as intended, and are used appropriately.